Success Metrics

Active Trials
1(33%)

Phase Distribution

Ph phase_2
1
33%
Ph phase_4
1
33%

Phase Distribution

0

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution2 total trials
Phase 2Efficacy & side effects
1(50.0%)
Phase 4Post-market surveillance
1(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Terminated(1)
Other(1)

Detailed Status

Recruiting1
Withdrawn1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
N/A
Most Advanced
Phase 4

Trials by Phase

Phase 21 (50.0%)
Phase 41 (50.0%)

Trials by Status

recruiting133%
withdrawn133%
unknown133%

Recent Activity

1 active trials
Showing 3 of 3
recruitingphase_4

Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study

NCT07410039
withdrawnphase_2

Eculizumab For Acute Attack of Neuromyelitis Optica Spectrum Disorder

NCT06673394
unknown

Efgartigimod in Acute Neuromyelitis Optica Spectrum Disorders

NCT06118398

Clinical Trials (3)

Showing 3 of 3 trials
NCT07410039Phase 4

Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study

Recruiting
NCT06673394Phase 2

Eculizumab For Acute Attack of Neuromyelitis Optica Spectrum Disorder

Withdrawn
NCT06118398

Efgartigimod in Acute Neuromyelitis Optica Spectrum Disorders

Unknown

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3